Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice - PubMed (original) (raw)

. 2007 Feb 15;85(3):681-91.

doi: 10.1002/jnr.21159.

Affiliations

• PMID: 17171705
• DOI: 10.1002/jnr.21159

Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice

Franziska Richter et al. J Neurosci Res. 2007.

Abstract

It has been hypothesized that exposures to neurotoxic pesticides together with aging and genetic factors increase the risk for developing Parkinson's disease (PD) which is characterized by a progressive degeneration of the nigrostriatal dopaminergic pathway. Chronic treatment with the pesticide rotenone has been reported to induce parkinsonism in rats. Although transgenic mice (but not transgenic rats) are available to investigate the importance of environmental factors in genetically predisposed animals, the effects of chronic rotenone exposure have so far not been examined in intact mice. Therefore, we investigated the effects of chronic exposure to rotenone (2.5 or 4.0-5.0 mg/kg s.c. for 30-45 days) in mice aged 2.5, 5, or 12 months. During the treatment period, the effects on vitality and motor behavior were investigated. Furthermore, the toxicity of rotenone on dopaminergic nigrostriatal neurons and peripheral tissues was examined. In comparison with control mice, rotenone-treated mice had a decreased spontaneous motor activity, but the density of nigral dopaminergic neurons failed to show any significant changes, except for a tendency to decrease in old mice treated with 4 mg/kg. At the tested doses, rotenone caused a moderate hepatic fatty degeneration. The data indicate that rotenone is not able to cause the neuropathological characteristics of PD in mice under these testing paradigms, which were similar to those of the rotenone rat model. Further studies will have to clarify whether genetic mouse models of PD might be more sensitive to the neurotoxic effects of rotenone.

PubMed Disclaimer

Similar articles

• Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
  Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama S. Takeuchi H, et al. J Neurosci Res. 2009 Feb;87(2):576-85. doi: 10.1002/jnr.21869. J Neurosci Res. 2009. PMID: 18803299
• Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
  Richter F, Hamann M, Richter A. Richter F, et al. Brain Res. 2008 Jan 10;1188:148-56. doi: 10.1016/j.brainres.2007.09.083. Epub 2007 Oct 12. Brain Res. 2008. PMID: 18035334
• Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
  Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. Inden M, et al. J Neurochem. 2007 Jun;101(6):1491-1504. doi: 10.1111/j.1471-4159.2006.04440.x. J Neurochem. 2007. PMID: 17459145
• Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
  Schmidt WJ, Alam M. Schmidt WJ, et al. J Neural Transm Suppl. 2006;(70):273-6. J Neural Transm Suppl. 2006. PMID: 17017541 Review.
• Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease.
  Moretto A, Colosio C. Moretto A, et al. Neurotoxicology. 2011 Aug;32(4):383-91. doi: 10.1016/j.neuro.2011.03.004. Epub 2011 Mar 23. Neurotoxicology. 2011. PMID: 21402100 Review.

Cited by

• Behavioral phenotyping of mouse models of Parkinson's disease.
  Taylor TN, Greene JG, Miller GW. Taylor TN, et al. Behav Brain Res. 2010 Jul 29;211(1):1-10. doi: 10.1016/j.bbr.2010.03.004. Epub 2010 Mar 6. Behav Brain Res. 2010. PMID: 20211655 Free PMC article. Review.
• Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity.
  Hineno A, Kaneko K, Yoshida K, Ikeda S. Hineno A, et al. Neurochem Res. 2011 Nov;36(11):2127-35. doi: 10.1007/s11064-011-0537-8. Epub 2011 Jun 26. Neurochem Res. 2011. PMID: 21706374 Free PMC article.
• Benefits of betanin in rotenone-induced Parkinson mice.
  Thong-Asa W, Jedsadavitayakol S, Jutarattananon S. Thong-Asa W, et al. Metab Brain Dis. 2021 Dec;36(8):2567-2577. doi: 10.1007/s11011-021-00826-0. Epub 2021 Aug 26. Metab Brain Dis. 2021. PMID: 34436745
• Model fusion, the next phase in developing animal models for Parkinson's disease.
  Manning-Bog AB, Langston JW. Manning-Bog AB, et al. Neurotox Res. 2007 Apr;11(3-4):219-40. doi: 10.1007/BF03033569. Neurotox Res. 2007. PMID: 17449461 Review.
• Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.
  Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH. Pan-Montojo F, et al. PLoS One. 2010 Jan 19;5(1):e8762. doi: 10.1371/journal.pone.0008762. PLoS One. 2010. PMID: 20098733 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley